Characterization of an Archaeal Multidrug Transporter with a Unique Amino Acid Composition*

Shira NinioDagger and Shimon Schuldiner§

From the Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, 91904 Jerusalem, Israel

Received for publication, December 23, 2002, and in revised form, January 27, 2003

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The Smr family of multidrug transporters consists of small membrane proteins that extrude various drugs in exchange with protons rendering cells resistant to these drugs. Smr proteins identified to date have been found only in Eubacteria. In this work we present the cloning and characterization of an Smr protein from the archaeon Halobacterium salinarum, the first Smr in the archaeal kingdom. The protein, named Hsmr, was identified through sequence similarity to the Smr family, and the DNA sequence was cloned into an Escherichia coli expression system. Hsmr is heterologously expressed in a functional form despite the difference in lipid composition of the membrane and the lower salt in the cell and its environment. Cells harboring the Hsmr plasmid transport ethidium bromide in an uncoupler-sensitive process and gain resistance to ethidium bromide and acriflavine. Hsmr binds tetraphenylphosphonium (TPP+) with a relatively low affinity (KD ~200 nM) at low salt concentration that increases (KD ~40 nM) upon the addition of 2 M of either NaCl or KCl. The Hsmr protein contains many of the signature sequence elements of the Smr family and also a high content of negative residues in the loops, characteristic of extreme halophiles. Strikingly, Hsmr is composed of over 40% valine and alanine residues. These residues are clustered at certain regions of the protein in domains that are not important for activity, as judged from lack of conservation and from previous studies with other Smr proteins. We suggest that this high content of alanine and valine residues is a reflection of a "natural" alanine and valine scanning necessitated by the high GC content of the gene. This phenomenon reveals significant sequence elements in small multidrug transporters.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Multidrug transporters actively remove toxic compounds from the cytoplasm of cells. They are widespread from bacteria to man and have been associated with multidrug resistance (1, 2). Many multidrug transporters have been identified to date and classified into several protein families (3, 4). Proteins in the Smr family of small multidrug resistance proteins are ~110-amino acids long and extrude various drugs in exchange with protons, thereby rendering bacteria resistant to these compounds (5, 6). Several Smr proteins have been characterized, purified, and reconstituted in a functional form (7, 8). Most posses a single membrane-embedded charged residue, Glu-14, conserved in more than sixty homologous proteins (8), which was shown to be part of a binding site common to protons and substrates (9, 10). The basic oligomeric structure detected in two-dimensional crystals of EmrE, an E. coli Smr, is a dimer (11). Radiolabeled substrate binding to purified EmrE and negative dominance experiments support the contention that the functional unit of the protein is an oligomer formed by two dimers (12-14).

In the absence of high-resolution structure, it would be useful to study the effect of multiple changes on the function of the protein. This is a complicated task to perform using site-directed mutagenesis, because designing an effective combination of mutations is not straightforward. One way to tackle this problem is by analyzing a set of homologues that provide natural, more complex, and less biased mutants (8). However, also with these mutants it is not always possible to identify suppressor or complimentary substitutions throughout the protein. Here we describe a special case that demonstrates an approach to overcome this problem. We report the first identification and characterization of an Smr protein from Archaea, the third domain of the universal phylogenetic tree (15). This protein, named Hsmr, was cloned from the archaeon H. salinarum based on sequence similarity to the Smr family. Hsmr was heterologously expressed in E. coli cells in a functional form despite the difference in lipid composition of the membrane and the lower salt in the cell and its environment. Hsmr renders cells resistant to the effect of multiple drugs and catalyzes the active efflux of ethidium from the cells. Detergent-solubilized Hsmr binds the high affinity substrate tetraphenylphosphonium (TPP+)1 in a salt-dependent manner: at low salt with a KD of 200 nM, and 40 nM at high salt. The Hsmr protein contains many of the signature sequence elements defining the Smr family. However, it also has a highly unusual sequence displaying some unique characteristics. It is composed of over 40% valine and alanine residues, which are distributed throughout the protein, often concentrated at areas where there is no sequence conservation. We suggest that this phenomenon is the outcome of a natural process of alanine and valine "scanning" that is necessitated by the high GC content of the gene.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Bacterial Strains and Plasmids-- E. coli JM109 (16) and E. coli BL21(DE3) (Novagen, Madison, WI) were used throughout this work. The plasmids used are pT7-7 (17), pT7-7 EmrE-His (12), and pT7-7 Hsmr-His. The latter was constructed as follows: the hsmr gene (OE3652F in the H. salinarum data base www.halolex.mpg.de) was cloned by polymerase chain reaction using as template genomic DNA from H. salinarum (provided by Prof. M. Mevarech, Faculty of Life Sciences, Tel Aviv University, Israel). Primers were designed to overlap with each end of the gene and included sites for restriction enzymes NdeI and EcoRI. The gene was cloned into the pT7-7-His vector, which was obtained by removing the emrE gene from vector pT7-7-EmrE-His with restriction enzymes NdeI and EcoRI. The start codon was modified from GTG to ATG.

Resistance to Toxic Compounds-- Resistance to toxic compounds was tested after overnight growth in 2xYT liquid media consisting of 1.6% (w/v) tryptone, 1% (w/v) yeast extract, and 0.5% (w/v) NaCl.

Efflux of Ethidium in Whole Cells-- Efflux of ethidium in whole cells was assayed essentially as described (7), except that E. coli BL21(DE3) cells were used. The cells were grown at 37 °C in LB medium, when the culture reached A600 ~0.4, isopropyl-1-thio-beta -D-galactopyranoside (IPTG) was added to 0.5 mM. Two hours later the cells were centrifuged and resuspended in minimal medium A supplemented with 0.05% NaCl, 1 mM MgSO4, 0.1 mM CaCl2, and 0.36% glucose. At this point, ethidium and carbonyl cyanide m-chlorophenylhydrazone (CCCP) were added to a final concentration of 1 µg/ml and 40 µM, respectively, and the cells were incubated for 60 min at 37 °C. The cells were collected by centrifugation and quickly resuspended in medium containing the same ethidium concentration without CCCP, and fluorescence was measured in a PerkinElmer fluorimeter (Luminescence Spectrometer LS-5) with exciting light at 545 nm and emission at 610 nm.

Overexpression and Purification of Hsmr-- E. coli BL21(DE3) cells bearing plasmid pT7-7 Hsmr-His were grown at 37 °C in 2xYT medium. When the culture reached A600 ~0.8, IPTG was added to 0.5 mM. Two hours later the cells were harvested by centrifugation, washed once with buffer containing 150 mM NaCl, 10 mM Tris, pH 7.5, 250 mM sucrose, 2.5 mM MgSO4, and 0.5 mM dithiothreitol, and resuspended in the same buffer containing 15 µg/ml DNaseI (5 ml buffer/g cells). Membranes were prepared by disrupting the cells using a Microfluidics microfluidizer processor (M-110EHi). Non-disrupted cells were separated by centrifugation, and the membranes were collected by ultracentrifugation at 300,000 × g for 60 min. The membrane pellet was resuspended in the same buffer, frozen in liquid air, and stored at -70 °C. Hsmr-His was purified by solubilizing membranes (0.25 mg of total protein) in SDS-Urea buffer (2% SDS, 6 M urea, 15 mM Tris, pH 7.5) for 15 min at 25 °C. Solubilized material was added to equilibrated Ni-NTA beads (Qiagene, GmbH, Hilden, Germany), and incubated for one hour at room temperature in the presence of 25 mM imidazole. Unbound material was discarded, the beads were washed once in the same buffer, and the protein was eluted in 200 mM imidazole. A sample was analyzed on SDS-PAGE.

TPP+ Binding Assay-- TPP+ binding was assayed essentially as described previously (12). Membranes were solubilized with 1% n-dodecyl-beta -maltoside (DDM), (Anatrace, Inc., Maumee, Ohio) in Na-buffer (150 mM NaCl, 15 mM Tris-Cl, pH 7.5) and immobilized on Ni-NTA beads. After two washes with Na buffer supplemented with 0.08% DDM, 200 µl of buffer containing 10 nM [3H]TPP+ (27 Ci/mmol, Amersham Biosciences) were added and the samples were incubated for 15 min at 4 °C. In each experiment, the values obtained in a control reaction, with 100 µM unlabeled TPP+, were subtracted. All binding reactions were performed in duplicate.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Hsmr Has a Remarkable Amino Acid Composition-- The Hsmr protein (Fig. 1A) was identified based on sequence similarity to EmrE, an E. coli protein belonging to the Smr family of multidrug resistance proteins. The gene encoding for Hsmr is very rich in GC (68% GC), whereas the percentage of coding GC in the H. salinarum genome is slightly lower (65%). At the amino acid level Hsmr shares 54% similarity and 43% identity with the EmrE protein. Hsmr is of particular interest because it is the first Smr protein found in the Archaea kingdom. A simple comparison of the amino acid composition of Hsmr and EmrE reveals some striking differences, which are summarized in Fig. 1B. The number of charged residues greatly differs between the two proteins. Both proteins have a glutamate at position 14, the only charged residue in the trans-membrane domain. This glutamate residue is conserved throughout the Smr family (3, 8) and was shown to have a central role in the transport mechanism of EmrE (12, 18). However, although EmrE has only two additional negatively charged residues, Hsmr has seven. They are located in putative hydrophilic loops of the protein, four of them in pairs, a pattern found in other proteins of halophilic organisms (Fig. 1, A and B). The overall number of charged residues in Hsmr is eleven, eight of which are negative, two histidines and one highly conserved lysine at position 22. A high content of negatively charged amino acids has been reported before in other halophilic proteins, and is suggested to have a stabilizing effect at high salt concentrations (19).


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 1.   Secondary structure and amino acid composition of Hsmr. A, model of the secondary structure of Hsmr based on hydropathy calculations (29) and on analogy to EmrE. Putative transmembrane helices are shown as gray cylinders. Positively charged residues are highlighted, and negatively charged residues are marked in black circles. B, the number of selected residues is given for EmrE (of a total of 110) and Hsmr (112). In the cloned Hsmr the initiation codon was modified so that it codes for methionine.

The proportion of hydrophobic residues is similar in the two proteins; however, the composition is very different. Hsmr contains more alanine and valine residues, 19 and 26 compared with 9 and 5 in EmrE, respectively. Thus, Hsmr displays a remarkable amino acid composition of over 40% valine and alanine residues. In parallel, the amount of isoleucine residues also changes from 15 in EmrE to only 3 in Hsmr. A small difference is observed in the number of glycines (11 in Hsmr, 12 in EmrE), leucines (12 and 16, respectively) and phenylalanines (4 and 5, respectively) (not shown). Hsmr contains no cysteine residues and a single tryptophan at position 63, a fully conserved residue. Stevens and Arkin (20) found a strong correlation between the GC content of a genome, and the ratio of (Val+Ala)/(Ile+Phe) residues of its membrane proteins. The higher the GC content of a genome, the higher the amount of valine and alanine residues. This correlation is explained by a codon bias toward GC-rich codons, together with a need to retain a certain level of hydrophobicity in a membrane-spanning region. In hsmr the codons used for alanine and valine are, exclusively, the ones with the highest GC content: GTG and GTC for valine, and GCG and GCC for alanine. The distribution of valine and alanine residues within the trans-membrane helices of Hsmr is not random. Many of these abundant residues appear to be clustered in structural domains, as can be seen in the helical-wheel projection of the trans-membrane helices of Hsmr (Fig. 2). Particularly stunning is the situation in helices 1 and 4. Residues that are highly conserved throughout the Smr family (8) are located on the opposite face of the helix from where the valine and alanine residues are clustered (Fig. 2, arrows). A similar distribution is observed in additional Smr proteins from other GC-rich organisms (not shown). This dramatic phenomenon may reflect the outcome of an evolutionary process leading to the replacement of all residues not essential for function with either valine or alanine. In a sense this resembles the result of an alanine scan mutagenesis experiment, pointing out instantaneously the residues that are important for the function of the protein, and therefore cannot be replaced with valine or alanine.


View larger version (81K):
[in this window]
[in a new window]
 
Fig. 2.   Alanine and valine clustering in Hsmr. A helical-wheel projection of the four trans-membrane helices of Hsmr. Alanine and valine residues are highlighted. Residues fully conserved, or partially conserved, within the Smr-family are marked by thick and thin arrows, respectively.

Hsmr Confers Resistance Against Cytotoxic Compounds-- Such a high alanine and valine content could be very useful in identifying domains important for function in Smr proteins. Therefore, we tested whether Hsmr can be functionally expressed. E. coli JM109 cells carrying the plasmids pT7-7 Hsmr, pT7-7 EmrE-His, or pT7-7 (vector alone) were tested for resistance to ethidium bromide, acriflavine, and methyl viologen. Cells expressing Hsmr grow in the presence of ethidium bromide up to 500 µM, to the same extent as cells expressing EmrE, whereas cells with vector alone display an IC50 of ~130 µM (Fig. 3A). In acriflavine, however, Hsmr cells display an intermediate resistance, with an IC50 of ~70 µM, whereas vector alone cells have an IC50 of around 20 µM, and EmrE-His cells are only inhibited by 25% at 120 µM acriflavine (Fig. 3B). Hsmr cells are not resistant to methyl viologen and display an IC50 of 75 µM, similar to that of vector alone cells, whereas EmrE-His cells can grow in the presence of up to 200 µM methyl viologen (Fig. 3C). Hsmr, therefore, functions as a multidrug resistance protein but displays a different substrate-specificity relative to that of EmrE.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 3.   Resistance to toxic compounds and drug efflux activity. E. coli JM109 cells carrying plasmids pT7-7 Hsmr-His (black-triangle), pT7-7 EmrE-His (black-square), or pT7-7 mock vector (), were grown in liquid media containing the indicated amounts of ethidium bromide (A), acriflavine (B), or Methyl viologen (C), as described under "Experimental Procedures." D, E. coli BL21 (DE3) cells harboring the plasmid pT7-7 Hsmr-His (left), or pT7-7 (right) were grown in LB to mid-logarithmic phase and then induced with 0.5 mM IPTG for 2 h. The cells were then centrifuged and resuspended in minimal medium containing ethidium bromide and CCCP, as described under "Experimental Procedures." After 60 min of incubation at 37 °C, the cells were washed quickly in CCCP-free medium and monitored for fluorescence. 40 µM CCCP was added where indicated.

Hsmr Catalyzes Ethidium Efflux in Whole Cells-- We further explored Hsmr function by directly testing its ability to catalyze the transport of ethidium bromide in whole cells. Entry of ethidium into cells is manifested by an increase in the fluorescence due to binding to nucleic acids (7, 21). Cells overexpressing either Hsmr or mock vector were treated with the uncoupler CCCP to facilitate the entry of ethidium into the cells, as previously described (7). After 60 min of incubation with ethidium (1 µg/ml) and CCCP (40 µM) the cells were collected by centrifugation and rapidly resuspended in medium containing the same concentration of ethidium, but without uncoupler. Upon removal of the uncoupler from Hsmr overexpressing cells, a rapid decrease in fluorescence is observed, even before the tracing begins, and is completed in less than 7 min (Fig. 3D, left). This decrease in fluorescence, which represents removal of ethidium from the cells against a concentration gradient, is completely reversed upon addition of CCCP (Fig. 3D, left). As expected, in cells harboring a control vector no decrease in fluorescence was observed (Fig. 3D, right). These results demonstrate that Hsmr catalyzes the active removal of ethidium in whole cells.

The Hsmr Dimer Is Resistant to Denaturant Treatment-- Expression levels were tested in membranes prepared from IPTG induced E. coli BL21 (DE3) cells harboring the plasmid pT7-7 Hsmr-His. The His-tagged Hsmr protein was purified from the membranes using a Ni-NTA column. The purified protein was analyzed on SDS-PAGE, alongside purified samples of EmrE (Fig. 4A). Hsmr reaches high levels of expression in E. coli membranes, up to 2 mg per 1 liter culture. As seen in Fig. 4A, the EmrE monomer displays an apparent Mr of 14,000. This value is close to the theoretical value of molecular mass calculated for a protein the size of EmrE or Hsmr (not shown). Surprisingly, Hsmr displays an apparent Mr of 30,000, suggesting that the dimeric complex of Hsmr does not dissociate, even in the presence of SDS. Furthermore, a small amount of protein corresponding to the Hsmr tetramer can also be observed (Fig. 4A). The protein was challenged with an anti-His antibody and also specifically radiolabeled, and in both cases it co-migrated with the Coomassie-stained protein (not shown). Attempts to dissociate the dimer were made by modifying the treatment of the sample before loading on the gel. These treatments included solubilization in various detergents and boiling of the purified protein; however, they yielded no visible monomers on the gel. Monomers were observed only after extraction of diluted protein in a mixture of chloroform and methanol (not shown).


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 4.   Expression, purification and activity of Hsmr. E. coli BL21 (DE3) cells carrying the plasmid pT7-7 Hsmr-His were grown in rich media, and protein expression was induced using 0.5 mM IPTG for two hours. The cells were harvested, and membranes were obtained by a single pass through a microfluidizer device, followed by ultracentrifugation. A, His-tagged Hsmr was purified from the E. coli membranes by solubilization in SDS-urea buffer and binding to Ni-NTA beads. A sample (equivalent to 25 µg total membrane protein) was analyzed on SDS-PAGE alongside a sample of purified EmrE (0.5 µg). B, increasing amounts or the E. coli membranes expressing Hsmr were solubilized in 1% DDM and assayed for [3H]TPP+ binding as described under "Experimental Procedures."

Solubilized Hsmr Binds [3H]TPP+ and Interacts with Several Other Drugs-- A very convenient functional assay of detergent-solubilized EmrE has been previously developed (12). Here we show that DDM-solubilized Hsmr also specifically binds [3H]TPP+ in a dose-dependent manner (Fig. 4B) in the range up to 50 µg of protein, leveling off at the high protein amounts, because of substrate depletion. To test interaction with other known substrates of EmrE, the compounds were tested for their ability to inhibit the binding reaction. The results are shown in Fig. 5. Methyl viologen had no effect on [3H]TPP+ binding to Hsmr, as expected from the inability of Hsmr to confer resistance against this compound in living cells (see Fig. 3C). Benzalkonium, ethidium, and acriflavine inhibit [3H]TPP+ binding to Hsmr in the µM range (Fig. 5), suggesting that they specifically interact with Hsmr. These results are in accordance with the phenotype presented in Fig. 3, and together they demonstrate the function of Hsmr as a multidrug protein, which can interact in a specific manner with different drugs.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of different drugs on the binding of [3H]TPP+ to Hsmr. Membranes from cells expressing His-tagged Hsmr (50 µg of total membrane protein) were solubilized with 1% DDM and assayed for [3H]TPP+ binding as described under "Experimental Procedures." To determine the effect of various drugs on the binding they were added to the binding solution in the indicated concentrations.

Salt Dependence of Hsmr-- H. salinarum, from which the Hsmr protein originates, normally resides in extreme environments where the salt concentration reaches very high values of 4-5 M (22). It was therefore interesting to examine the effect of salt on the activity of Hsmr. For that purpose solubilized membranes from cells expressing either Hsmr or EmrE were assayed for [3H]TPP+ binding at increasing concentrations of NaCl, KCl, or LiCl. Hsmr-binding activity is markedly stimulated in the presence of KCl, NaCl, and LiCl (Fig. 6A). As the concentration of salt rises from zero to 3.2 M an increase in the binding activity is observed, saturating around the high salt concentration. Both KCl and NaCl brought about a 6-7-fold increase in the binding upon addition of about 3.0 M salt. A smaller effect is seen in LiCl that induces only a 4-fold increase at similar concentrations. The binding activity of EmrE is not affected by the salt concentration and remains constant up to 3 M KCl, NaCl, or LiCl (Fig. 6B). To understand the mechanism underlying this salt effect we measured the binding affinity at the different salt concentrations. We found that the binding affinity increases 5-fold, from 200 to 40 nM, upon the addition of 2 M NaCl.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 6.   Salt dependence of Hsmr. Solubilized Hsmr-His (50 µg of total membrane protein) (A) or EmrE-His (1 µg of total membrane protein) (B) were assayed for [3H]TPP+ binding as described under "Experimental Procedures." To test the salt dependence of the binding, immobilized Hsmr was washed once in buffer containing 0.08% DDM, 15 mM Tris, pH 8, and either NaCl (), KCl (black-triangle), or LiCl (black-square) at the indicated concentrations, and the binding reaction was carried on in the same buffer. Bound TPP+ is plotted as the percent of TPP+ bound when no salt is added to the binding solution.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The first Smr protein from the archaeon H. salinarum was identified based on sequence similarity. Its unusual alanine and valine content, and the clustering of these residues in certain domains, suggested possible functional implications. Therefore, we set out to probe the activity of the protein. Hsmr was functionally expressed in E. coli membranes, to high levels. Proteins from extremely halophilic bacteria are adapted to a very high salt environment (above 3 M), and usually denature in the absence of high salt, resulting in a non-functional protein (22). Nonetheless, expression of the hsmr gene in E. coli results in the production of a protein that is functional in vivo as judged from drug resistance phenotype and from a whole cell ethidium efflux assay. Hsmr is active in a wide range of conditions because it does not strictly require salt for its activity. It is also able to function in the E. coli membrane, which has a lipid composition very different from the archaeal membrane it originated from (23, 24). The stability of the protein is also apparent when analyzed on SDS-PAGE. The Hsmr dimer stays intact even at high concentrations of SDS. This unusual phenomenon of an SDS-stable oligomer has been reported before with the dimer of glycophorine A (25) as well as for the phospholamban pentamer (26). Attempts to dissociate the Hsmr dimer have been made by using different solubilization conditions and by heating the protein sample before loading on the gel. The protein retained its "dimeric" mobility on the gel unless diluted and extracted in an organic solvent. Hsmr is also functional in vitro, in its DDM-solubilized form, where it specifically binds the substrate TPP+ in a dose-dependent manner. Although the protein retains its binding activity even in the absence of salt, this activity is greatly enhanced at high salt concentrations as a result of an increase in the affinity of the protein to TPP+. This salt effect appears to be a general one because it is observed in both NaCl and KCl as well as in LiCl and MgCl2 (not shown) to a lesser extent.

The Smr proteins are not as ubiquitous in the Archaea as in the Eubacteria. Only three other homologues can be identified until now, all of them in various Methanosarcinoma species (not shown). Hsmr was identified based on sequence similarity to the Smr family, yet was found to have a unique sequence composition. Compared with other Smr proteins, Hsmr contains many negative charges, located mostly at the hydrophilic loops of the protein. This phenomenon is observed in many halophilic proteins and is said to contribute much to their stability in high salt (27). Hsmr has only one positive charge, Lys-22, which is fully conserved in the Smr family, and two histidine residues facing the opposite side of the membrane. Because there are so few positive charges, which are distributed quite symmetrically on both sides of the membrane, it is difficult to apply the von Heijne rule for topology prediction (28) to this protein. The inapplicability of this rule with Smr proteins has been demonstrated before and was suggested to result from their small size (18).

The most striking feature of Hsmr is the fact that it is built of over 40% valine and alanine residues, clustered at certain regions of the protein. This clustering is in domains that do not seem important for activity. According to Stevens and Arkin (20), and discussed earlier, there exists a strong positive correlation between the GC content of a genome and the amount of valine and alanine residues found in membrane proteins it codes for. This correlation is explained by a codon bias toward amino acids coded predominately by GC nucleotides, together with a need to retain certain physical properties within a trans-membrane domain. The rise in the abundance of valine residues is also thought to be compensating for the lack of AT-coded amino acids, particularly isoleucine, with which it shares similar physical properties. The alanine and valine codons are GCN and GTN, respectively, of which only GCG and GCC (for alanine) and GTG and GTC (for valine) are present in the hsmr gene. Although codon bias could be fulfilled also by glycine and leucine, the frequency of these amino acids does not increase in proteins from organisms with high GC content (20). We speculate that glycine would not be hydrophobic enough and could allow too much flexibility of the helix; leucine may be bulkier than necessary.

The distribution of valine and alanine residues in the first trans-membrane domain of Hsmr correlates well with information deduced from extensive site-directed mutagenesis of the same trans-membrane domain in the homologous protein EmrE. EmrE mutations in residues in the same face of the helix as Glu-14 have effects on the catalytic activity of the protein, whereas mutations on the other face of the helix have no effect (31). Strikingly, the face tolerant to mutations is the one predominated by alanine residues in Hsmr. Without a high-resolution structure of an Smr we can only speculate about the location of an alanine-rich face in a membrane protein. Alanine is a small, relatively hydrophobic amino acid. Because of its size it could provide an interface for tight packing of two helices (30). On the other hand, its hydrophobicity is high enough for interaction with lipids in the membrane.

Hsmr is therefore a case of natural alanine and valine mutagenesis. Multiple sites in the protein, located in regions not important for activity, have become through evolution occupied by valine or alanine residues. The advantage of analyzing sequences such as that of Hsmr is that the outcome of replacements in more than one position can be seen within the same protein. Multiple replacements are more informative than single ones. The latter depend at times on the properties of amino acids in positions other than the ones modified. This could be because of size, charge, or other properties. Multiple replacements are difficult to design, therefore the analysis of valine- and alanine-rich sequences could greatly facilitate their planning or even serve as ready made "mutants," a quick alternative for experimentation.

We found that the valine and alanine clustering is observed in additional membrane proteins from H. salinarum, and therefore may be part of a general phenomenon. A full genomic and statistical analysis is required to conclude whether this phenomenon can be used to reveal significant sequence elements in membrane proteins in general. If this is indeed a general phenomenon it could be used to devise an algorithm predicting important regions within a Val+Ala-rich membrane protein sequence, without the need for additional information. This prediction, in turn, could be projected on to non-Val+Ala-rich homologues, providing a general tool for a quick preliminary prediction of significant regions within a given membrane protein.

    FOOTNOTES

* This work was supported by grants from the Deutsche-Israeli Program (Federal Ministry of Education, Science and Research-BMBF-International Bureau at the German Aerospace Center Technology), Grant NS16708 from the National Institutes of Health, and Grant 463/00 from the Israel Science Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Recipient of a Yeshaya Horowitz Foundation fellowship.

§ To whom correspondence should be addressed. Tel.: 972-2-6585992; Fax: 972-2-5634625; E-mail: Shimon.Schuldiner@huji.ac.il.

Published, JBC Papers in Press, January 27, 2003, DOI 10.1074/jbc.M213119200

    ABBREVIATIONS

The abbreviations used are: TPP+, tetraphenylphosphonium; IPTG, isopropyl-1-thio-beta -D-galactopyranoside; CCCP, carbonyl cyanide m-chlorophenylhydrazone; DDM, n-dodecyl-beta -maltoside; Ni-NTA, nickel-nitrilotriacetic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Nikaido, H. (1994) Science 264, 382-388[Medline] [Order article via Infotrieve]
2. Gottesman, M. M., Pastan, I., and Ambudkar, S. V. (1996) Curr. Opin. Genet. Dev. 6, 610-617[CrossRef][Medline] [Order article via Infotrieve]
3. Marger, M., and Saier, M. (1993) Trends Biochem. Sci. 18, 13-20[CrossRef][Medline] [Order article via Infotrieve]
4. Paulsen, I. T., Brown, M. H., and Skurray, R. A. (1996) Microbiol Rev. 60, 575-608[Medline] [Order article via Infotrieve]
5. Schuldiner, S., Granot, D., Mordoch, S. S., Ninio, S., Rotem, D., Soskin, M., Tate, C. G., and Yerushalmi, H. (2001) News Physiol. Sci. 16, 130-134[Abstract/Free Full Text]
6. Schuldiner, S., Granot, D., Steiner, S., Ninio, S., Rotem, D., Soskin, M., and Yerushalmi, H. (2001) J. Mol. Microbiol. Biotechnol. 3, 155-162[Medline] [Order article via Infotrieve]
7. Yerushalmi, H., Lebendiker, M., and Schuldiner, S. (1995) J. Biol. Chem. 270, 6856-6863[Abstract/Free Full Text]
8. Ninio, S., Rotem, D., and Schuldiner, S. (2001) J. Biol. Chem. 276, 48250-48256[Abstract/Free Full Text]
9. Yerushalmi, H., and Schuldiner, S. (2000) FEBS Lett. 476, 93-97[CrossRef][Medline] [Order article via Infotrieve]
10. Yerushalmi, H., and Schuldiner, S. (2000) Biochemistry 39, 14711-14719[CrossRef][Medline] [Order article via Infotrieve]
11. Tate, C. G., Kunji, E. R., Lebendiker, M., and Schuldiner, S. (2001) EMBO J. 20, 77-81[Abstract/Free Full Text]
12. Muth, T. R., and Schuldiner, S. (2000) EMBO J. 19, 234-240[Abstract/Free Full Text]
13. Yerushalmi, H., Lebendiker, M., and Schuldiner, S. (1996) J. Biol. Chem. 271, 31044-31048[Abstract/Free Full Text]
14. Rotem, D., Sal-Man, N., and Schuldiner, S. (2001) J. Biol. Chem. 276, 48243-48249[Abstract/Free Full Text]
15. Pace, N. R. (1997) Science 276, 734-740[Abstract/Free Full Text]
16. Yanish-Perron, C., Viera, J., and Messing, J. (1985) Gene 33, 103-199[CrossRef][Medline] [Order article via Infotrieve]
17. Tabor, S., and Richardson, C. (1985) Proc. Natl. Acad. Sci. 82, 1074-1078[Abstract]
18. Yerushalmi, H., and Schuldiner, S. (2000) J. Biol. Chem. 275, 5264-5269[Abstract/Free Full Text]
19. Mevarech, M., Frolow, F., and Gloss, L. M. (2000) Biophys. Chem. 86, 155-164[CrossRef][Medline] [Order article via Infotrieve]
20. Stevens, T. J., and Arkin, I. T. (2000) Protein. Sci. 9, 505-511[Abstract]
21. Lambert, B., and Le Pecq, J. B. (1984) Biochemistry 23, 166-176[Medline] [Order article via Infotrieve]
22. Madern, D., Ebel, C., and Zaccai, G. (2000) Extremophiles 4, 91-98[CrossRef][Medline] [Order article via Infotrieve]
23. Albers, S. V., van de Vossenberg, J. L., Driessen, A. J., and Konings, W. N. (2001) Extremophiles 5, 285-294[Medline] [Order article via Infotrieve]
24. van de Vossenberg, J. L., Driessen, A. J., and Konings, W. N. (1998) Extremophiles 2, 163-170[CrossRef][Medline] [Order article via Infotrieve]
25. Furthmayr, H., and Marchesi, V. T. (1976) Biochemistry 15, 1137-1144[Medline] [Order article via Infotrieve]
26. Watanabe, Y., Kijima, Y., Kadoma, M., Tada, M., and Takagi, T. (1991) J Biochem. (Tokyo) 110, 40-45[Abstract]
27. Elcock, A. H., and McCammon, J. A. (1998) J. Mol. Biol. 280, 731-748[CrossRef][Medline] [Order article via Infotrieve]
28. von Heijne, G. (1986) EMBO J. 5, 3021-3027
29. Kyte, J., and Doolittle, R. F. (1982) J. Mol. Biol. 157, 105-132[Medline] [Order article via Infotrieve]
30. Jiang, S., and Vakser, I. A. (2000) Proteins 40, 429-435[CrossRef][Medline] [Order article via Infotrieve]
31. Gutman, N., Steiner-Mordoch, S., and Schuldiner, S. (February 16, 2003) J. Biol. Chem. 10.1074/jbc.M213120200


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.